| Literature DB >> 36165114 |
Almudena Pérez-Torres1, Alberto Caverni Muñoz2, Luis Miguel Lou Arnal3, Alejandro Sanz Paris4, Concepción Vidal Peracho5, Juan La Torre Catalá6, Rafael Sánchez Villanueva7, Secundino Cigarrán Guldris8, Filomeno Trocoli González7, Ángel Nogueira Pérez9, Ana Sanjurjo Amado10, M Elena González García11, Guillermina Barril Cuadrado9.
Abstract
The presence of malnutrition in patients with Chronic Kidney Disease (CKD) is high, it can be made worse by SARS-CoV2 infection. The nutritional assessment should be adapted to minimize the infection, recommending monitoring: weight loss percentage, body mass index (BMI), loss of appetite, analytical parameters and functional capacity using the dynamometer. As well as the sarcopenia assessment using the SCARF scale, and the possibility of using the GLIM criteria in those patients who have been tested positive by MUST. It is important to adapt the nutritional recommendations in the caloric and protein intake, to the CKD stage and to the SARS-CoV2 infection stage. In patients with hypercatabolism, to prioritize preserving the nutritional status (35 kcal/kg weight/day, proteins up to 1.5 g/kg/day). The rest of the nutrients will be adapted to CKD stage and the analytical values. In the post-infection stage, a complete nutritional assessment is recommended, including sarcopenia. The energy and protein requirements in this phase will be adapted to the nutritional status, with special attention to the loss of muscle mass. Dietary recommendations need to be tailored to side effects of SARS-CoV-2 infection: anorexia, dysphagia, dysgeusia, and diarrhea. Anorexia and hypercatabolism makes it difficult to meet the requirements through diet, therefore the use of oral nutritional supplements is recommended as well as the enteral or parenteral nutrition in severe phases.Entities:
Keywords: CKD; Diet; Dieta; ERC; Nutrición; Nutrition; Nutritional supplementation; Requerimientos; Requirements; SARS-CoV-2; Suplementación nutricional
Mesh:
Substances:
Year: 2021 PMID: 36165114 PMCID: PMC8531001 DOI: 10.1016/j.nefroe.2021.10.002
Source DB: PubMed Journal: Nefrologia (Engl Ed) ISSN: 2013-2514
Figure 1Relationship of infection by SARS-CoV-2 and PEW.
CV: cardiovascular; PEW: protein energy waste; HTN: arterial hypertension.
Figure 2Basic scheme of evaluation in patients infected by SARS-CoV-2.
Table of nutritional requirements according to CKD stage in patients with mild/moderate SARS-CoV-2 infection.
| Energy | Proteins | Potassium (g/day) | Phosphorus (g/day) | ||
|---|---|---|---|---|---|
| (Mild SARS-CoV-2) | (SARS-CoV-2 moderate) | ||||
| Stages 1−2 | 30−35 | 1.0 + proteinuria | Up to 1.4 | Individualize | Individualize |
| Stages 3−5 no in dialysis | 30−35 | 0.8−1.0 + proteinuria | 0.8−1.0 + proteinuria | If elevated: 2−4 | If elevated: 0.8−1 |
| Hemodialysis | 30−35 | 1.2 | 1.2g | If elevated: 2−3 | If elevated: 0.8−1 |
| Peritoneal dialysis | 30−35 | 1.3 | 1.3−1.5 | If elevated: 3−4 | If elevated: 0.8−1 |
| Transplant | 30−35 | 1.0 + proteinuria | Up to 1.4 | Individualize | Individualize |
CKD: chronic kidney disease; TCV: total caloric value.
Calculate the requirements according to actual weight, ideal weight or adjusted weight.
Quantify glucose uptake.
In the case of proteinuria, increase protein intake by 1 g of protein per gram of proteinuria in 24 h urine volume.
Individualize according to analytical values.
1.5 g / kg / day in hypercatabolic states.
Nutritional requirements according to the stage of CKD in patients after SARS-CoV-2 infection.
| Energy | Proteins | Potassium (g/day) | Phosphorus (g/day) | |||
|---|---|---|---|---|---|---|
| Risk or mild malnutrition | Moderate or severe malnutrition | Risk or mild malnutrition | Moderate or severe malnutrition | |||
| Stages 1–2 | 30−35 | 30−40 | 1.0 + proteinuria | Up to 1.4 | Individualize | Individualize |
| Stages 3−5 no dialysis | 30−35 | 30−40 | 0.8−1.0 + proteinuria | 0.8−1.0 + proteinuria | If raised: 2−4 | If raised: (0.8−1) |
| Hemodialysis | 30−35 | 30−40 | 1.2 | 1.2 | If raised: 2−4 | If raised: (0.8−1) |
| Peritoneal dialysis | 30−35 | 30−40 | 1.2−1.3 | 1.2−1.5 | If raised: up to 4 | If raised: (0.8−1) |
| Transplant | 30−35 | 30−40 | 1.0 + proteinuria | Up to 1.4 | Individualize | Individualize |
CKD: chronic kidney disease.
Calculate requirements according to actual weight, ideal weight or adjusted weight.
Account for glucose uptake.
In the case of proteinuria, increase protein intake by 1 g of protein per gram of proteinuria in 24 h urine volume.
Individualize based on analytical values.
1.5 g / kg / day in hypercatabolic states.
Recommendations of nutritional supplements in patients with CKD and SARS-CoV-2 infection.
| Stages of CKD | Recommendations of Nutritional supplements |
|---|---|
| 1−2 | - Hypercaloric/hyperproteic - Immunomodulatory formulas - If there is a high loss of muscle mass, consider formulas enriched in leucine or HMB |
| 3–5 (not in dialysis) | - Specific formulas for CKD |
| - Immunomodulatory formulas | |
| - If there is high loss of muscle mass, consider formulas enriched in leucine or HMB | |
| Patients on RRT: hemodialysis or peritoneal dialysis | |
| HD: combine with adequate HD schemes ( | - Specific formulas for CKD - Immunomodulatory formulas - If there is a high loss of muscle mass, consider formulas enriched in leucine or HMB - In peritoneal dialysis consider the use of protein modules and ctheglucose absorption |
| Trasplante: Ajustar to the stage of CKD and consider immunosuppressive drugs | - Hypercaloric / hyperprotein - Specific formulas for CKD |
DM: diabetes mellitus; CKD: chronic kidney disease; HMB: hydroxymethylbutyrate.
Note: Evaluate the administration of supplements of vitamins D, Zn and Se.
It is recommended to perform physical activity adapted to the characteristics of the patient as a complement to nutritional treatment.
In case of DM, regardless of the stage of CKD, consider the use of specific enteral nutrition formulas for diabetics.
In hypercatabolic patients, assess the use of specific formulas for CKD rich in protein in low volume, since the important goal is the treatment of acute malnutrition rather than the risk of CKD progression.